Sergio A. Giralt, MD

Belumosudil conferred high overall response rates at two dose levels among patients with chronic graft-versus-host disease, according to results of the phase 2 ROCKstar study presented at the virtual ASH Annual Meeting and Exposition.

Older patients with myelodysplastic syndrome who underwent donor-matched allogeneic hematopoietic stem cell transplant had significantly improved survival outcomes compared with those who did not have a matched donor, study results showed.

Ruxolitinib conferred a higher overall response rate than best available therapy for certain patients with chronic graft-versus-host disease, according to results of an analysis presented at the virtual ASH Annual Meeting and Exposition.